Literature DB >> 25305042

[Intravitreal fibrinolysis and retinal vein occlusion].

T Bertelmann1, T Stief, W Sekundo, M Witteborn, S Strodthoff, S Mennel, N Nguyen, M Koss.   

Abstract

BACKGROUND: The aim of this study was to analyze and compare intravitreal activity and concentrations of different components of the fibrinolytic cascade in eyes with central retinal vein occlusion (CRVO) as well as branch RVO (BRVO) and healthy controls. These results were correlated with corresponding intravitreal vascular endothelial growth factor (VEGF) concentrations as a biomarker for the severity of blood-retina barrier (BRB) breakdown.
MATERIAL AND METHODS: Vitreous samples were obtained from 14 eyes with CRVO, 22 eyes with BRVO and 11 controls and the activities and concentrations of plasminogen, plasmin-alpha2-antiplasmin (PAP) and VEGF were analyzed.
RESULTS: Intravitreal activities and concentrations in the CRVO, BRVO and control groups were 2.07 ± 1.87%, 1.24 ± 1.12% and 0.38 ± 0.63% for functional plasminogen, 8.14 ± 7.07 ng/ml, 6.96 ± 4.8 ng/ml and 9.74 ± 10.98 ng/ml for PAP while respective results for VEG levels were 1269 ± 1318 pg/ml, 528 ± 543 pg/ml and 105 ± 116 pg/ml, respectively. There were significant differences in intravitreal functional plasminogen and VEGF between the groups analyzed (in each case p < 0.001). Intravitreal functional plasminogen correlated with intravitreal VEGF concentrations (r = 0.478, p = 0.001). No adverse events or serious side effects occurred.
CONCLUSION: There were significant differences in intravitreal functional plasminogen and VEGF between eyes with CRVO, BRVO and controls. Intravitreal activity of plasminogen was significantly correlated with the severity of BRB breakdown in RVO affected eyes. The knowledge of intravitreal activities and concentrations of different components of the fibrinolytic cascade could offer new therapeutic strategies in RVO-affected eyes in the future.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25305042     DOI: 10.1007/s00347-014-3107-z

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  41 in total

1.  Microincision vitrectomy procedure using Intrector technology.

Authors:  Frank H Koch; Michael J Koss
Journal:  Arch Ophthalmol       Date:  2011-12

Review 2.  New functions of the fibrinolytic system in bone marrow cell-derived angiogenesis.

Authors:  Beate Heissig; Makiko Ohki-Koizumi; Yoshihiko Tashiro; Ismael Gritli; Kaori Sato-Kusubata; Koichi Hattori
Journal:  Int J Hematol       Date:  2012-02-07       Impact factor: 2.490

3.  Fibrinolysis in normal vitreous liquid.

Authors:  Thomas Bertelmann; Thomas Stief; Reka Bölöni; Stephan Schulze; Yaroslava Wenner; Walter Sekundo; Stefan Mennel
Journal:  Blood Coagul Fibrinolysis       Date:  2014-04       Impact factor: 1.276

4.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

Authors:  David M Brown; Peter A Campochiaro; Rishi P Singh; Zhengrong Li; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Roman G Rubio; Wendy Yee Murahashi
Journal:  Ophthalmology       Date:  2010-04-09       Impact factor: 12.079

5.  Vitreous concentrations of TPA and plasminogen activator inhibitor are associated with VEGF in proliferative diabetic vitreoretinopathy.

Authors:  L O Hattenbach; A Allers; H O Gümbel; I Scharrer; F H Koch
Journal:  Retina       Date:  1999       Impact factor: 4.256

6.  Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion.

Authors:  H Noma; H Funatsu; M Yamasaki; H Tsukamoto; T Mimura; T Sone; T Hirayama; H Tamura; H Yamashita; A Minamoto; H K Mishima
Journal:  Eye (Lond)       Date:  2006-07-07       Impact factor: 3.775

7.  Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation.

Authors:  Julie L Gasperini; Amani A Fawzi; Ani Khondkaryan; Linda Lam; Lawrence P Chong; Dean Eliott; Alexander C Walsh; John Hwang; SriniVas R Sadda
Journal:  Br J Ophthalmol       Date:  2011-07-26       Impact factor: 4.638

8.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

Authors:  Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup
Journal:  Ophthalmology       Date:  2010-04-24       Impact factor: 12.079

9.  The natural course of central retinal vein occlusion.

Authors:  P M Quinlan; M J Elman; A K Bhatt; P Mardesich; C Enger
Journal:  Am J Ophthalmol       Date:  1990-08-15       Impact factor: 5.258

Review 10.  Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review.

Authors:  Amelie Pielen; Nicolas Feltgen; Christin Isserstedt; Josep Callizo; Bernd Junker; Christine Schmucker
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.